131 related articles for article (PubMed ID: 32546073)
1. Uveitis Induced by Biological Agents Used in Cancer Therapy.
Deitch-Harel I; Raskin E; Habot-Wilner Z; Friling R; Amer R; Kramer M
Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1370-1374. PubMed ID: 32546073
[No Abstract] [Full Text] [Related]
2. Drug-induced ocular inflammation.
Samalia P; Sims J; Niederer R
N Z Med J; 2020 Dec; 133(1527):83-94. PubMed ID: 33332330
[TBL] [Abstract][Full Text] [Related]
3. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
[TBL] [Abstract][Full Text] [Related]
4. Recurrent Episodes with Serous Retinal Detachment and Anterior Uveitis in a Patient Using Nivolumab (Anti -PD-1 Antibody) Therapy: A case report and literature review.
Yilmaz Tugan B; Ozkan B; Sonmez O
Semin Ophthalmol; 2021 Nov; 36(8):794-799. PubMed ID: 33780309
[No Abstract] [Full Text] [Related]
5. Uveitis associated with cancer immunotherapy: long-term outcomes.
Fardeau C; Bencheqroun M; Levy A; Bonnin S; Ferchaud MA; Fardeau L; Coscas F; Bodaghi B; Lebrun-Vignes B
Immunotherapy; 2021 Dec; 13(18):1465-1481. PubMed ID: 34709074
[TBL] [Abstract][Full Text] [Related]
6. Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies.
Noble CW; Gangaputra SS; Thompson IA; Yuan A; Apolo AB; Lee JM; Papaliodis GN; Kodati S; Bishop R; Magone MT; Sobrin L; Sen HN
Ocul Immunol Inflamm; 2020 Aug; 28(6):854-859. PubMed ID: 31013173
[TBL] [Abstract][Full Text] [Related]
7. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
Najjar YG; Navrazhina K; Ding F; Bhatia R; Tsai K; Abbate K; Durden B; Eroglu Z; Bhatia S; Park S; Chowdhary A; Chandra S; Kennedy J; Puzanov I; Ernstoff M; Vachhani P; Drabick J; Singh A; Xu T; Yang J; Carvajal R; Manson D; Kirkwood JM; Cohen J; Sullivan R; Johnson D; Funchain P; Shoushtari A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581057
[TBL] [Abstract][Full Text] [Related]
9. Bilateral Drug-Induced Uveitis and Epiretinal Membrane during the Treatment of a Metastatic Cutaneous Melanoma.
Mozo Cuadrado M; Tabuenca Del Barrio L; Compains Silva E
Ocul Immunol Inflamm; 2021 Apr; 29(3):543-545. PubMed ID: 31755788
[No Abstract] [Full Text] [Related]
10. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab.
Abu Samra K; Valdes-Navarro M; Lee S; Swan R; Foster CS; Anesi SD
Eur J Ophthalmol; 2016 Apr; 26(3):e46-8. PubMed ID: 26692064
[TBL] [Abstract][Full Text] [Related]
11. New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient.
Miserocchi E; Cimminiello C; Mazzola M; Russo V; Modorati GM
Can J Ophthalmol; 2015 Feb; 50(1):e2-4. PubMed ID: 25677296
[No Abstract] [Full Text] [Related]
12. Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature.
Papavasileiou E; Prasad S; Freitag SK; Sobrin L; Lobo AM
Ocul Immunol Inflamm; 2016; 24(2):140-6. PubMed ID: 25760920
[TBL] [Abstract][Full Text] [Related]
13. Ocular Complications of Checkpoint Inhibitors and Immunotherapeutic Agents: A Case Series.
Parikh RA; Chaon BC; Berkenstock MK
Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1585-1590. PubMed ID: 32643982
[No Abstract] [Full Text] [Related]
14. Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes.
Dow ER; Yung M; Tsui E
Ocul Immunol Inflamm; 2021 Jan; 29(1):203-211. PubMed ID: 32815757
[No Abstract] [Full Text] [Related]
15. Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.
Shin E; Lim DH; Han J; Nam DH; Park K; Ahn MJ; Kang WK; Lee J; Ahn JS; Lee SH; Sun JM; Jung HA; Chung TY
BMC Ophthalmol; 2020 Jan; 20(1):19. PubMed ID: 31918686
[TBL] [Abstract][Full Text] [Related]
16. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
[TBL] [Abstract][Full Text] [Related]
17. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S
J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336
[TBL] [Abstract][Full Text] [Related]
18. Bilateral Hypotony Maculopathy Associated With Ipilimumab and Nivolumab Therapy Unresponsive to Corticosteroid Treatment.
Ahmed AA; Hiya FE; Eichenbaum DA
Ophthalmic Surg Lasers Imaging Retina; 2023 May; 54(5):301-304. PubMed ID: 37078857
[TBL] [Abstract][Full Text] [Related]
19. Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: A case report.
Numata S; Iwata Y; Okumura R; Arima M; Kobayashi T; Watanabe S; Suzuki K; Horiguchi M; Sugiura K
J Dermatol; 2018 Jan; 45(1):113-114. PubMed ID: 28225147
[No Abstract] [Full Text] [Related]
20. [Bilateral uveitis associated with nivolumab therapy].
Rémond AL; Barreau E; Le Hoang P; Bodaghi B
J Fr Ophtalmol; 2018 Jun; 41(6):536-539. PubMed ID: 29958705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
